Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.

Poti F, Bot M, Costa S, Bergonzini V, Maines L, Varga G, Freise H, Robenek H, Simoni M, Nofer JR.

Thromb Haemost. 2012 Mar;107(3):552-61. doi: 10.1160/TH11-08-0583. Epub 2012 Jan 11.

PMID:
22234485
2.

SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet.

Potì F, Ceglarek U, Burkhardt R, Simoni M, Nofer JR.

Atherosclerosis. 2015 May;240(1):212-5. doi: 10.1016/j.atherosclerosis.2015.03.020. Epub 2015 Mar 16.

PMID:
25801013
3.

KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice.

Potì F, Gualtieri F, Sacchi S, Weißen-Plenz G, Varga G, Brodde M, Weber C, Simoni M, Nofer JR.

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1505-12. doi: 10.1161/ATVBAHA.113.301347. Epub 2013 May 2.

4.

FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.

Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA.

Circulation. 2007 Jan 30;115(4):501-8. Epub 2007 Jan 22.

5.

Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.

Poti F, Costa S, Bergonzini V, Galletti M, Pignatti E, Weber C, Simoni M, Nofer JR.

Vascul Pharmacol. 2012 Aug 19;57(1):56-64. doi: 10.1016/j.vph.2012.03.003. Epub 2012 Mar 20.

PMID:
22459073
6.

Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats.

Liu Q, Rehman H, Shi Y, Krishnasamy Y, Lemasters JJ, Smith CD, Zhong Z.

PLoS One. 2012;7(7):e41834. doi: 10.1371/journal.pone.0041834. Epub 2012 Jul 25.

7.

The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.

Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C.

Mol Cancer Ther. 2015 Dec;14(12):2744-52. doi: 10.1158/1535-7163.MCT-15-0279. Epub 2015 Oct 22.

8.

Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

Beljanski V, Lewis CS, Smith CD.

Cancer Biol Ther. 2011 Mar 1;11(5):524-34. Epub 2011 Mar 1.

9.

Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.

Qin Z, Dai L, Trillo-Tinoco J, Senkal C, Wang W, Reske T, Bonstaff K, Del Valle L, Rodriguez P, Flemington E, Voelkel-Johnson C, Smith CD, Ogretmen B, Parsons C.

Mol Cancer Ther. 2014 Jan;13(1):154-64. doi: 10.1158/1535-7163.MCT-13-0466. Epub 2013 Oct 18.

10.

Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis.

Snider AJ, Ruiz P, Obeid LM, Oates JC.

PLoS One. 2013;8(1):e53521. doi: 10.1371/journal.pone.0053521. Epub 2013 Jan 3.

11.

Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis.

Lai WQ, Irwan AW, Goh HH, Howe HS, Yu DT, Valle-Oñate R, McInnes IB, Melendez AJ, Leung BP.

J Immunol. 2008 Dec 1;181(11):8010-7.

12.

Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.

French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD.

J Pharmacol Exp Ther. 2010 Apr;333(1):129-39. doi: 10.1124/jpet.109.163444. Epub 2010 Jan 8.

13.

Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.

Xun C, Chen MB, Qi L, Tie-Ning Z, Peng X, Ning L, Zhi-Xiao C, Li-Wei W.

J Exp Clin Cancer Res. 2015 Sep 4;34:94. doi: 10.1186/s13046-015-0205-y.

14.

The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen.

Schröder M, Richter C, Juan MH, Maltusch K, Giegold O, Quintini G, Pfeilschifter JM, Huwiler A, Radeke HH.

Mol Immunol. 2011 May;48(9-10):1139-48. doi: 10.1016/j.molimm.2011.02.007. Epub 2011 Mar 23.

PMID:
21435724
15.

Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice.

Zhu H, Jin X, Zhao J, Dong Z, Ma X, Xu F, Huang W, Liu G, Zou Y, Wang K, Hu K, Sun A, Ge J.

J Cardiovasc Pharmacol. 2015 Jun;65(6):620-7. doi: 10.1097/FJC.0000000000000234.

16.

A novel sphingosine kinase inhibitor induces autophagy in tumor cells.

Beljanski V, Knaak C, Smith CD.

J Pharmacol Exp Ther. 2010 May;333(2):454-64. doi: 10.1124/jpet.109.163337. Epub 2010 Feb 23.

17.

Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.

White MD, Chan L, Antoon JW, Beckman BS.

Anticancer Res. 2013 Sep;33(9):3573-9.

PMID:
24023282
18.

Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice.

Wang J, Sjöberg S, Tia V, Secco B, Chen H, Yang M, Sukhova GK, Shi GP.

Atherosclerosis. 2013 Aug;229(2):304-9. doi: 10.1016/j.atherosclerosis.2013.05.025. Epub 2013 Jun 7.

19.

Sphingosine kinase inhibitor suppresses a Th1 polarization via the inhibition of immunostimulatory activity in murine bone marrow-derived dendritic cells.

Jung ID, Lee JS, Kim YJ, Jeong YI, Lee CM, Baumruker T, Billlich A, Banno Y, Lee MG, Ahn SC, Park WS, Han J, Park YM.

Int Immunol. 2007 Apr;19(4):411-26. Epub 2007 Feb 16.

PMID:
17307797
20.

Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan Z, Ogretmen B, Smith C, Kang Y.

Blood. 2014 Sep 18;124(12):1915-25.

Supplemental Content

Support Center